日期: | 2022/07/25 |
---|---|
作者: | The Arbitrators |
文件編號: | WT/DS583/ARB25 |
附件下載: | WTDS583ARB25.pdf |
因為版本問題,開啟附件時可能會出現錯誤訊息,如「檔案已損毀」的訊息,請您忽略此訊息,即可正常開啟 |
Turkey –
certain measures concerning the production,
importation and marketing of pharmaceutical products
Arbitration under Article 25 of the DSU
Award of the Arbitrators
Table of contents
2 MEASURES TAKEN TO STREAMLINE THE PROCEEDINGS
5 ARGUMENTS OF THE THIRD PARTIES
6.1
Relevant background information and the localisation requirement
6.1.1
Reimbursement of pharmaceutical products active in
the Annex 4/A list
6.1.2 The
localisation requirement
6.2
Articles III:4 and III:8(a) of the GATT 1994
6.2.1.4
The Panel's conclusion
6.2.2
Whether the Panel erred in its interpretation of Article III:8(a) of the
GATT 1994
6.2.2.1
Overview of Article III:8(a) of the GATT 1994
6.2.3
Application of Article III:8(a) of the GATT 1994
6.3
Article XX(b) of the GATT 1994
6.3.1.2
The declared objective of the measure and its importance
6.3.1.4
The Panel's conclusion
6.3.2
Whether the Panel erred in its interpretation of Article XX(b) of the
GATT 1994
6.3.2.3
Whether the Panel erred by relying on previous panel reports dealing with other
provisions
6.3.3
Whether the Panel erred in its application of Article XX(b) of the
GATT 1994
6.4
Article XX(d) of the GATT 1994
7.1
Articles III:4 and III:8(a) of the GATT 1994
7.2
Article XX(b) of the GATT 1994
7.3
Article XX(d) of the GATT 1994